Attorneys from Mintz,
Levin, Cohn, Ferris, Glovsky and Popeo, P.C.'s San Diego office
represented San Diego-based MabVax Therapeutics, Inc. in its previously
announced merger with a wholly owned subsidiary of Telik, Inc.
Prior to the July 8th merger, MabVax Therapeutics, Inc. was a
privately-held cancer immunotherapy company focusing on the development
of vaccine and antibody-based therapies for the treatment of cancer.
Telik, Inc. is a publicly-traded clinical stage drug development company
focused on discovering and developing small molecule drugs to treat
cancer. Through the transaction, the former MabVax stockholders became
the controlling stockholders of the publicly-traded Telik and MabVax's
management team beame the management team of Telik, resulting in MabVax
achieving access to the public markets through the merger.
Representing MabVax Therapeutics, Inc. in the transaction were Jeremy
D. Glaser, a Member and co-chair of Mintz Levin's Venture Capital &
Emerging Companies Practice and Sebastian
E. Lucier, Melanie
D. Ruthrauff and Jenna
M. Shaffer, attorneys in the firm's Corporate & Securities Practice
practicing in the San Diego office.
For more information about Mintz Levin, please visit www.mintz.com.
[ Back To NFVZone's Homepage ]